Kalydeco (kuh-LYE-deh-koh), a new treatment for cystic fibrosis (CF)
March 2012
You'll hear about Kalydeco (kuh-LYE-deh-koh), a new treatment for cystic fibrosis (CF).
Kalydeco (ivacaftor) is the first drug that treats the underlying genetic mutation that causes CF...not just its symptoms.
Unfortunately, it'll only help the 4% of CF patients who have a rare genetic mutation. But in the future, you'll see drugs that target more common mutations that cause CF.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber Insights: APRN includes:
- Cutting-edge advice about new medications and how they fit into practice
- Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
- Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations
Already a subscriber? Log in
Volume pricing available. Get a quote